**Nuvig:
** The headline says Nuvig is dropping a Phase 2 trial, but the available search results do not include reliable details about which study or why it is being discontinued.
**Cerevance:
** On Oct. 7, 2026, Cerevance reported positive top-line results from its Phase 3 ARISE trial of solengepras, an add-on treatment for Parkinson’s patients experiencing motor fluctuations despite existing medication.
At the 150 mg dose, solengepras reduced daily “OFF” time—the periods when medication wears off and symptoms return—by 0.61 hours versus placebo after 12 weeks. The company also reported improvements in certain measures of “ON” time, daily living, and daytime sleepiness.
Cerevance said the drug was generally well tolerated and plans to discuss the results and potential next steps with the FDA. These are company-reported top-line results, not an approval.
Sources:
A Takeda spinout builds case for its Parkinson's drug
Health News — Live Headlines - Many Angles
Cerevance Announces Positive Phase 3 ARISE Results
Parkinson's Pill Met Goals in Late-Stage Trial, Cerevance Says
Cerevance rescues its Parkinson's drug with phase 3 win
parkinsons.org › research › pipelineParkinson's Disease Treatment Pipeline: Drugs in Development ...
Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDA
Cerevance Showcases Positive Phase 2 Results ...
Cerevance’s novel Parkinson’s drug nets a Phase III win
Cerevance fails phase 2 trial in early, untreated Parkinson's